ALLOGENIC ADIPOSE-DERIVED MESENCHYMAL STEM CELLS (AMSCs) FOR EPILEPSY DURING DEEP BRAIN STIMULATION (DBS) SURGERY

Primary Objective,Secondary Objective

This study is a non-randomized, open label, phase 1 clinical trial to evaluate the fesibility
 and safety of intrathalamic delivery of MSCs during standard of care DBS surgery for
 epilepsy.
 
 Subjects will be screened at our outpatient clinic and interested qualified subjects will be
 consented and offered participation in this trial. Once consent has been obtained, patients
 will undergo a standard preoperative evaluation which includes baseline laboratory values and
 a high-definition MRI. Patients will then undergo a stereotactic procedure for bilateral
 thalamic implantation of DBS leads through the ClearPoint® system. After the thalamic target
 for DBS is identified, cells will be infused directly into the anterior nucleus of the
 thalamus previous to lead implantation.
 
 Patients will be followed in the outpatient setting for up to a year after therapy
 application.
 
 Surgical, clinical, and radiographic data will be obtained during these visits